Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 1
1994 1
1995 1
1997 3
1998 3
1999 3
2000 1
2001 1
2002 3
2003 1
2004 3
2005 3
2006 1
2008 6
2009 5
2010 3
2011 5
2012 4
2013 4
2014 5
2015 6
2016 6
2017 7
2018 9
2019 8
2020 8
2021 11
2022 7
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
Direct cardiac effects of SGLT2 inhibitors.
Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ. Chen S, et al. Among authors: zuurbier cj. Cardiovasc Diabetol. 2022 Mar 18;21(1):45. doi: 10.1186/s12933-022-01480-1. Cardiovasc Diabetol. 2022. PMID: 35303888 Free PMC article. Review.
Cardiac metabolism as a driver and therapeutic target of myocardial infarction.
Zuurbier CJ, Bertrand L, Beauloye CR, Andreadou I, Ruiz-Meana M, Jespersen NR, Kula-Alwar D, Prag HA, Eric Botker H, Dambrova M, Montessuit C, Kaambre T, Liepinsh E, Brookes PS, Krieg T. Zuurbier CJ, et al. J Cell Mol Med. 2020 Jun;24(11):5937-5954. doi: 10.1111/jcmm.15180. Epub 2020 May 8. J Cell Mol Med. 2020. PMID: 32384583 Free PMC article. Review.
Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
Nikolaou PE, Mylonas N, Makridakis M, Makrecka-Kuka M, Iliou A, Zerikiotis S, Efentakis P, Kampoukos S, Kostomitsopoulos N, Vilskersts R, Ikonomidis I, Lambadiari V, Zuurbier CJ, Latosinska A, Vlahou A, Dimitriadis G, Iliodromitis EK, Andreadou I. Nikolaou PE, et al. Among authors: zuurbier cj. Basic Res Cardiol. 2022 May 17;117(1):27. doi: 10.1007/s00395-022-00934-7. Basic Res Cardiol. 2022. PMID: 35581445
Targeting metabolic pathways to treat cardiovascular diseases.
Glatz JFC, Zuurbier CJ, Larsen TS. Glatz JFC, et al. Among authors: zuurbier cj. Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165879. doi: 10.1016/j.bbadis.2020.165879. Epub 2020 Jun 18. Biochim Biophys Acta Mol Basis Dis. 2020. PMID: 32562699 Free article. No abstract available.
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ. Uthman L, et al. Among authors: zuurbier cj. Diabetologia. 2018 Mar;61(3):722-726. doi: 10.1007/s00125-017-4509-7. Epub 2017 Dec 2. Diabetologia. 2018. PMID: 29197997 Free PMC article.
Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells.
Uthman L, Li X, Baartscheer A, Schumacher CA, Baumgart P, Hermanides J, Preckel B, Hollmann MW, Coronel R, Zuurbier CJ, Weber NC. Uthman L, et al. Among authors: zuurbier cj. Biomed Pharmacother. 2022 Feb;146:112515. doi: 10.1016/j.biopha.2021.112515. Epub 2021 Dec 9. Biomed Pharmacother. 2022. PMID: 34896968 Free article.
NLRP3 Inflammasome in Cardioprotective Signaling.
Zuurbier CJ. Zuurbier CJ. J Cardiovasc Pharmacol. 2019 Oct;74(4):271-275. doi: 10.1097/FJC.0000000000000696. J Cardiovasc Pharmacol. 2019. PMID: 31356546 Review.
114 results